Source: Health Products Regulatory Authority (ZA) Publisher: GlaxoSmithKline South Africa (Pty) Ltd, 39 Hawkins Avenue, Epping Industria 1, 7460
TRELAVUE.
| Pharmaceutical Form |
|---|
|
Purple, biconvex, oval, film-coated tablets, debossed with "572 Trı" on one side. |
Each film-coated tablet contains 50 mg of dolutegravir as dolutegravir sodium, 600 mg of abacavir as abacavir sulphate and 300 mg of lamivudine.
| Active Ingredient |
|---|
|
Abacavir is a NRTI. It is a potent selective inhibitor of HIV-1 and HIV-2. Abacavir is metabolised intracellularly to the active moiety, carbovir 5'-triphosphate (TP). In vitro studies have demonstrated that its mechanism of action in relation to HIV is inhibition of the HIV reverse transcriptase enzyme, an event which results in chain termination and interruption of the viral replication cycle. |
|
Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral Deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle. |
|
Lamivudine is a nucleoside analogue which has activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Its main mode of action is as a chain terminator of viral reverse transcription. |
| List of Excipients |
|---|
|
Tablet Core: D-Mannitol Tablet coating: Opadry II Purple 85F90057 containing: Polyvinyl alcohol – part hydrolysed |
TRELAVUE tablets are packed into opaque, white High Density Polyethylene (HDPE) bottles and closed with white polypropylene child resistant closures, with a polyethylene faced induction heat seal liner. A silica gel desiccant is included in each bottle. The HDPE bottle is pigmented white with titanium dioxide and is packed into an outer cardboard carton.
GlaxoSmithKline South Africa (Pty) Ltd, 39 Hawkins Avenue, Epping Industria 1, 7460
49/20.2.8/0097
| Drug | Countries | |
|---|---|---|
| TRELAVUE | South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.